Recent advances basic science The role gut microbiota cancer treatment friend foe Wing Yin Cheng1 Chun Ying Wu2 Jun Yu 1 ABSTRACT The gut microbiota implicated cancer shown modulate anticancer drug efficacy Altered gut microbiota associated resistance chemo drugs immune checkpoint inhibitors ICIs supplementation distinct bacterial species restores responses anticancer drugs Accumulating evidence revealed potential modulating gut microbiota enhance efficacy anticancer drugs Regardless valuable findings preclinical models clinical data patients cancer thorough understanding interactions microbiota cancer therapy helps researchers identify novel strategy cancer prevention stratify patients effective treatment reduce treatment complication In review discuss scientific evidence role gut microbiota cancer treatment highlight latest knowledge technologies leveraged target specific bacteria contribute tumourigenesis First provide overview role gut microbiota cancer establishing links bacteria inflammation cancer treatment Second highlight mechanisms distinct bacterial species modulate cancer growth immune responses efficacy chemotherapeutic drugs ICIs Third demonstrate approaches modulate gut microbiota potential translational research Finally discuss limitations current microbiome research context cancer treatment ongoing efforts overcome challenges future perspectives INTRODUCTION The gut microbiota emerged critical player maintenance human health influencing GI tract distal organs brain liver pancreas1 2 As dysbiosis refers compositional functional alter ations gut microbiome contributes development pathological conditions including obesity35 diabetes68 neurodegenera tive diseases9 10 cancers1114 Notably bacterial infection induce cancer The colonisation Helicobacter pylori causes persistent inflammation leads gastritis driving gastric malignancy portion infected individuals Further analysis revealed H pylori promotes tumourigenesis activation βcatenin signalling pathway15 Conversely eradication H pylori decreases risk gastric cancer infected individuals supporting role early stages gastric carcino genesis16 Likewise colorectal cancer CRC Key messages The gut microbiota implicated cancer shown modulate efficacy anticancer treatment Altered gut microbiota associated resistance chemo drugs immune checkpoint inhibitors ICIs Modulating microbiota antibiotics probiotics faecal microbiota transplant nanotechnologies potentiate antitumour effects chemo drugs ICIs Preclinical clinical studies suggest use tumour associated bacteria diagnostic prognostic markers cancer Microbial signature stratify patients cancer effective treatment reduce treatment complication development cancer colon asso ciated specific bacteria Recently analysis faecal metagenomic samples patients CRC identified CRC enriched bacteria including Bacteroides fragilis Fusobacterium nucleatum Porphyromonas asaccharolytica Parvimonas micra Prevotella intermedia Alistipes finegoldii Ther manaerovibrio acidaminovorans poten tially serve diagnostic bacterial markers populations17 18 The correlation CRC enriched bacteria pathways lipopoly saccharide energy biosynthesis17 protein mucin catabolism carbohydrate degradation18 provides insights functional capacity CRC Moreover compelling evidence suggests microbial shifts highly distinct tumour stages Two patterns species elevation reported consisted continuous increase early stages onwards showed elevation early stages The shifts microbiome metabolome occurred early stages provide clues aetiology CRC19 An influx bacterial species originating oral cavity suggested play role CRC pathogenesis gut microbiome patients CRC exhibits higher species rich ness control subjects expan sion oral cavity associated species rarely present healthy gut20 In parallel large scale cross cohort studies faecal metagenomes establish link gut microbiome CRC identify microbiome signatures CRC accurately predict disease multiple datasets Microbial CRC biomarkers 1867 Additional material published online To view visit journal online http dx doi org 10 1136 gutjnl 2020 321153 1State Key Laboratory Digestive Disease Institute Digestive Disease The Department Medicine Therapeutics Li Ka Shing Institute Health Sciences CUHK Shenzhen Research Institute The Chinese University Hong Kong Hong Kong SAR China 2Division Translational Research Department Medical Research Taipei Veterans General Hospital Taipei Taiwan Institute Biomedical Bioinformatics School Medicine National Yang Ming University Taipei Taiwan College Public Health Graduate Institute Clinical Medicine China Medical University Taichung Taiwan Correspondence Dr Jun Yu Institute Digestive Disease The Department Medicine Therapeutics Chinese University Hong Kong New Territories Hong Kong junyu cuhk edu hk Received 18 March 2020 Revised 2 July 2020 Accepted 6 July 2020 Published Online First 5 August 2020 Authors employers 2020 Re use permitted CC BY NC No commercial use See rights permissions Published BMJ To cite Cheng WY Wu C Y Yu J Gut 20206918671876 Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153 Recent advances basic science identified cross cohort studies potentially enhance non invasive microbial diagnostic tests distinguishing CRC cases normal individuals Series vitro vivo studies highlight mechanisms gut microbiota promote tumouri genesis Gavage faecal samples patients CRC promotes colon carcinogenesis germ free conventional mice21 Additional mouse models demonstrate depleting microbiota suppresses lung cancer development induced Kras mutation p53 loss11 Bacteria reported promote inflammation cancer cell proliferation cytokine produc tion11 22 Indeed H pylori interleukin22 IL22 induce matrix metalloproteinase10 MMP10 gastric epithelial cells extracellular signal regulated kinase ERK pathway MMP10 induces inflammation production chemokine ligand 16 CXCL16 recruitment CD8 T cells damages gastric mucosa inhibiting tight junc tion proteins22 Besides animal models gastric organoids virulence factor CagA H pylori associates c Met receptor cellular proliferation23 Together studies illustrate interaction bacteria different components tumour microenvironment promote tumourigenesis Chronic inflammation plays important role carcinogen esis colitis susceptible IL10 deficient mouse model identi fies gut microbiota target inflammation influences progression CRC24 Colitis promotes tumourigenesis altering microbiota inducing expansion bacteria genotoxic capabilities24 Enterotoxigenic Bacteroides fragilis ETBF reported promote colon tumourigenesis stimulating exaggerated immune responses T helper 17 Th17 cells mouse CRC model25 Gavaging mice prone develop colon tumour Peptostreptococcus anaer obius bacteria implicated CRC demonstrates P anaerobius interacts toll like receptor 2 TLR2 TLR4 colon cells promotes CRC modu lation immune cell types including myeloid derived suppressor cells MDSCs tumour associated macrophages TAMs granulocytic tumour associated neutrophils26 27 Moreover Fusobacterium nucleatum key drivers CRC shown induce inflammatory oncogenic responses virulence factors including FadA Fap2 LPS28 29 In addition function modulating inflammation microbiota influences efficacy cancer treatment Preclinical data colon cancer mouse model identi fied Gammaproteobacteria key bacteria metabolise gemcitabine chemotheraoeutic drug inactive form cytidine deaminase30 Human pancreatic ductal adenocarcinoma PDAC samples contained elevated level Gammaproteo bacteria compared normal pancreas Culturing bacteria fresh human PDAC tumours human colon carcinoma cell lines rendered cell lines fully resistant gemcitabine30 The detection Gammaproteobacteria explain gemcit abine resistance PDAC patients targeting bacteria sensitise tumour gemcitabine treatment Collectively findings interactions gut micro biota host influence process tumouri genesis efficacy cancer treatment Alexander et al proposed TIMER mechanistic framework illustrate bacteria influence chemotherapy host terms translocation immunomodulation metabolism enzymatic degradation reduced diversity ecological variation31 32 The modulation cancer immunotherapies microbiota reported3337 In following sections explore mechanisms distinct bacterial species modulate efficacy chemotherapeutic drugs immune checkpoint inhibitors ICIs Next diverse approaches enhance cancer treatment altering microbiota discuss potential clinical application approaches BACTERIA THAT MAY IMPROVE CANCER THERAPY EFFICACY Multiple studies demonstrate therapeutic efficacy diminished absence gut microbiota suggesting different mechanisms commensal microbes modulate anticancer immune responses induced therapies Cyclophosphamide CTX approved chemotherapeutic drug shown alter composition intestinal microbiota mice promote translocation specific Gram positive bacteria secondary lymphoid organs stimulating production pathogenic Th17 cells share hallmarks T helper 1 Th1 cells Th17 cells37 38 Removal gut microbiota germ free mice mice treated antibiotics leads drug resistance CTX37 On hand genetic models consisting Escherichia coli Caenor habditis elegans elucidate complex interactions host bacteria fluoropyrimidines antimetabolite drugs commonly treat cancer32 Bacteria modulate efficacy fluoropyrimidines C elegans bacterial vitamin B6 B9 ribonucleotide metabolism figure 1 However role bacteria dietary nutrients drug efficacy remains elusive complex nature human body influenced intrinsic factors environmental factors Bacteria modulate efficacy chemotherapeutic drugs immunotherapy An early study mice receiving antibiotic cocktail supports altered microbiota impairs CpG oligonucleotide immunotherapy platinum chemotherapy With intact microbiota immunotherapy suppresses tumour growth tumour necrosis factor TNF production myeloid cells CD8 T cell response Conversely antibiotic treatment impairs TNF cytokine production immune cells including monocytes macrophages dendritic cells reduces tumour regression mice receiving immuno therapy These findings suggest TLR4 activation commensal microbes stimulate tumour associated myeloid cells produce inflammatory cytokines response immuno therapy improve patients outcome36 Deeper mech anism insights functions commensal bacteria interactions host promote design micro bial consortia improve efficacy cancer therapies BACTERIA THAT MAY PROMOTE CANCER GROWTH AND PROGRESSION In contrast commensal microbes boost immune cells fight cancer subsets pathogenic bacteria asso ciated development progression tumours Using subcutaneous liver metastases models pancreatic cancer colon cancer melanoma Sethi et al showed antibiotics mediated suppression tumour growth involved adaptive immunity This inhibitory effect attenuated Rag1 knockout mice deficient mature T B cells Mechanistically targeting microbiota led increased level interferon gamma IFNγ producing T cells decreased level IL 17a IL10 producing T cells39 Targeting pathogenic bacteria restore immune functions augment efficacy cancer therapies Fusobacterium nucleatum implicated types cancer including colorectal cancer19 4043 oesophageal 1868 Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153 Recent advances basic science Figure 1 Mechanisms gut bacteria modulate anticancer drug efficacy Bacterial species influence efficacy chemo drugs immune checkpoint inhibitors diverse mechanisms Bacteria modulate efficacy 5 FU bacterial vitamin B6 B9 ribonucleotide metabolism Inhibiting bacterial deoxynucleotide metabolism promotes efficacy 5 FU Barnesiella intestinihominis Enterococcus hirae play critical role antitumour effect chemo drug cyclophosphamide Removing bacterial species results drug resistance cyclophosphamide Mechanistically E hirae translocates small intestine secondary lymphoid organs stimulates production pTh17 cells B intestinihominis accumulates colon promotes infiltration IFNγproducing γδT cells cancer lesions treatment cyclophosphamide In addition Fusobacterium nucleatum acts TLR4 MYD88 induces selective loss miR 18a miR 4802 activates autophagy promotes chemoresistance patients Furthermore antitumour effect anti CTLA4 treatment depends Bacteroides species Bacteroides fragilis colonises mucosal layer induces T helper 1 immune responses lymph nodes promotes maturation intratumorous dendritic cells mediating anticancer activity immune checkpoint inhibitor 5 FU 5 fluorouracil IFNγ interferon gamma pTh17 cells pathogenic T helper 17 cells cancer44 gastric cancer45 head neck squamous cell carci noma46 pancreatic cancer47 Studies cell lines mouse models demonstrated FadA adhesin F nucleatum binds epithelial cadherin E cadherin induces βcatenin signalling modulates inflammatory oncogenic responses promote tumourigenesis Abolishing binding F nucleatum E cadherin synthetic peptide suppresses CRC cell growth In concordance preclinical data patients CRC display elevated level fadA colon tissues compared normal individuals Further examination patients RNA revealed concomitant induction Wnt7b NFkB2 expression suggesting critical role fadA F nucleatum induced oncogenic inflammatory responses28 Another mechanism F nucleatum promote cancer growth illustrated studies examined functions immune cells presence F nucleatum These studies revealed Fap2 protein F nucleatum inhibited natural killer NK cell cytotoxicity interaction T cell immu noglobulin ITIM domain TIGIT regulated localisation bacteria colorectal tumours induced cell death human lymphocytes4850 Besides pro tumourigenic effects F nucleatum contributes chemoresistance enriched CRC patients recurrence post chemotherapy40 Mech anistically F nucleatum acts TLR4 MYD88 induces selective loss miR 18a miR4802 activates autophagy promotes chemoresistance patients CRC40 Targeting F nucleatum associated pathways amelio rate CRC patient outcomes figure 1 Similar F nucleatum enrichment P anaerobius associated CRC P anaerobius adheres cancer cells normal colonic epithelial cells surface protein putative cell wall binding repeat 2 PCWBR2 interacts α2β1 integrin expressed colonic cells subsequently activates PI3K Akt pathway promoting cell proliferation inflammation nuclear factor kappa light chain enhancer activated B cells NFκB cascade With reported functions P anaerobius promoting cell proliferation triggering proinflammatory tumour microenvironment recruit ment tumour infiltrating MDSCs TAMs27 efforts directed examining effect bacterial species chemotherapies cancer immunotherapies Furthermore radiotherapy exerts potent immune modula tory effect tumour associated antigen cross presentation cytolytic CD8 T cells IFNγ51 A study melanoma Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153 1869 Recent advances basic science lung cancer models revealed vancomycin antibiotic targeting Gram positive bacteria potentiated radiotherapy induced antitumour response mice increasing CD8 T cell infiltration IFNγ expression supplementation sodium butyrate key metabolite Gram positive bacteria abolished effect51 The level Gram positive bacteria poten tially influences patients response radiotherapy MICROBIAL BIOMARKERS FOR THERAPY EFFICACY The antitumour immune response CTX shown enhanced bacterial species Lactobacillus johnsonii Enterococcus hirae Barnesiella intestinihominis identified mouse models37 52 Mechanistically E hirae translo cates small intestine secondary lymphoid organs increases intratumorous CD8Treg ratio B intes tinihominis accumulates colon promotes infiltra tion IFNγproducing γδT cells cancer lesions Oral gavage E hirae restores antitumour effect CTX ablated antibiotics treatment Additional mouse model identified nucleotide binding oligomerisation domain containing protein 2 inhibitor activity E hirae B intertinihominis52 Similarly antitumour effect anti cytotoxic T lymphocyte associated protein 4 CTLA4 treatment depends distinct Bacteroides species Germ free antibiotics treated mice respond anti CTLA4 treatment gavaging mice Bacteroides fragilis induces Th1 immune responses lymph nodes promotes maturation intratumorous dendritic cells restoring response CTLA blockade Similar observation patients reveals efficacy CTLA4 anti body associated T cell responses mediated B fragilis Bacteroides thetaiotaomicron35 In addition Bifidobacterium breve Bifidobacterium longum species reported augment dendritic cell function induce CD8 T cell priming accumulation tumour microenvironment33 34 The supplementation bacterial strains enhance therapeutic efficacy ICIs patients cancer Furthermore bacteria shown suppress melanoma growth attenuating unfolded protein response UPR signalling pathway mediating antitumour immunity Mice lacking ubiquitin ligase RNF5 exhibit altered gut microbiota correlates decreased expression UPR increased expression inflammasome components Transfer 11 bacterial strains enriched Rnf5 mice promotes antitu mour immunity represses melanoma growth germ free wild type mice53 In accordance mouse data patients respond immune checkpoint therapy exhibit signifi cantly reduced level UPR components53 Modulation selec tive bacterial species enhance cancer immunotherapy improve outcomes non responders Complementing preclinical mouse models studies patients highlight potential use gut microbiota predicting treatment outcome Analysing faecal microbiota composition metastatic melanoma MM patients receiving ipilimumab ICI targeting CTLA4 revealed patients enriched level Faecalibacterium Firmicutes associated longer survival increased occurrence ipilimumab induced colitis54 Similar CTLA4 programmed cell death protein 1 PD1 inhibitory receptors downregulate effector functions suppress immune response PD1 blockade leads significant tumour regression subset patients cancer5559 A metage nomic analysis faecal samples nonsmall cell lung cancer NSCLC renal cell carcinoma RCC patients receiving anti PD1 treatment indicated non responders reduced levels Akkermansia muciniphila shown promote recruitment CCR9CXCR3CD4 T lympho cytes tumour microenvironment IL12 pathway60 On hand studies patients melanoma validated presence commensal microbes potentiated anti tumour effects PD1 blockade responders61 62 Notably responders display higher alpha diversity enriched levels Ruminococcaceae Faecalibacterium associated enhanced antigen presentation T cell function tumour microenvironment61 Taken ratio benefi cial bacteria non beneficial bacteria suggested predict clinical response62 Importantly different cancer types cancer treatments chemotherapy vs immunotherapy sample types stool vs tissue approaches determine micro bial profile 16S vs metagenomic sequencing lead biases subsequently identification different species bene ficial bacteria Faecalibacterium prausnitzii instance plays conflicting role inflammation F prausnitzii asso ciated improved clinical response immune checkpoint blockade54 63 shown mitigate intestinal inflammation context inflammatory bowel disease64 With ability produce short chain fatty acids SCFAs induce Treg cells IL10 F prausnitzii expected promote anticancer immune responses However recent study demonstrated SCFAs enhanced memory potential activated CD8 T cells suggesting F prausnitzii poten tiate antitumour immune response promoting CD8 T cells long term survival memory cells65 Likewise pathogenic bacteria serve diagnostic prognostic markers Metagenomic data patients cancer indicated F nucleatum enriched CRC tissues compared normal tissues19 66 67 Not level F nucleatum increase degree malignancy40 associates metastasis68 69 Further study 309 subjects showed complementing faecal immunochem ical test FIT detection F nucleatum improved diagnostic performance FIT colon cancer screening70 Additional analysis human CRC cohorts unveils features F nucleatum associated CRC including right sided colon location CpG island methylation phenotype high CIMP H high level microsatellite instability MSI H poor prognosis7173 CRC MSI high status gener ally harbour numerous mutations generate immunogenic peptides mismatch repair deficiency These alter ations encourage antitumour immune response leading favourable prognosis better response immunother apies Considering effects MSI status Food Drug Administration FDA approved use anti PD1 anti bodies pembrolizumab nivolumab CRC high MSI status Interestingly study 1041 patients rectal colon cancer demonstrated association F nucleatum tumour infiltrating lymphocytes TIL differed tumour MSI status The presence F nucleatum negatively asso ciated TIL MSI high tumours positively associated TIL non MSI high tumours The differential associ ation F nucleatum immune cells tumour MSI status suggests F nucleatum interacts MSI status mediate immune response tumour74 The F nucleatum induced changes immune response influence cancer patients treatment outcome overall survival Despite obser vations patients cancer strongly suggest use F nucleatum prognostic marker relationships 1870 Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153 F nucleatum methylation status tumours F nucleatum right sided colon location remain elucidated In addition CRC recent studies liver cancer75 pancreatic cancer1 2 39 elucidated mechanisms bacteria modulate immune profile efficacy cancer treatment Pushalkar et al demonstrated human mouse PDAC exhibited distinct bacterial composition compared normal pancreas Bacterial ablation antibiotics repro grammed PDAC tumour microenvironment enhanced efficacy ICI reducing level MDSCs inducing M1 macrophage differentiation promoting CD8 T cell activation2 A recent study liver cancer delineated mechanism bacteria diminish antitumour immunity liver Using multiple mouse models Ma et al identified Clostridium species important players regulation bile acids turn influenced production chemokine CXCL16 liver sinusoidal endothelial cells CXCL16 recruits natural killer T NKT cells tumour inhibiting growth primary metastatic liver cancer75 In accordance preclinical data bile acids correlated CXCL 16 expression human liver sinusoidal endothelial cell line non tumour liver tissues patients liver cancer Targeting Clostridium species restore antitumour immunity liver suppress tumour growth75 MODULATION OF CANCER THERAPYASSOCIATED TOXICITIES BY THE MICROBIOTA GI surgery including preoperative cleansing oral intra venous antibiotics alters microbiota lead compli cations infection anastomotic leakage76 77 These complications ameliorated modulating microbiota evidence suggests specific bacteria including Lactoba cillus spp A muciniphila regulate intestinal wound healing process reactive oxygen species dependent formyl peptide receptors dependent mechanisms76 78 79 A study germ free mice colonised B thetaiotaomicron indi cated bacteria function regulating expression genes involved nutrient absorption mucosal barrier fortification angiogenesis80 In contrast beneficial bacteria maintain intestinal function epithelial integrity pathogenic bacteria Serratia marcescens Pseudomonas aeru ginosa promote development anastomotic leakage81 82 Therefore selective inhibition pathogens simultaneous preservation good bacteria prior surgery minimise risk complications Similar surgery treatment ICIs result adverse events including colitis Metagenomic sequencing revealed certain bacteria display altered profile patients cancer suffering checkpoint blockade induced colitis Of note elevated level Bacteroidetes microbial genetic pathways involved polyamine transport B vitamin biosynthesis shown associated resistance develop ment colitis patients cancer receiving ipilimumab The identified microbial biomarkers predict patients risk developing ipilimumab induced colitis83 Supplementation cocktail bacteria including Bacteroidales Burkholderiales faecal microbiota transplant FMT treatment shown ameliorate ICI induced colitis antibiotic treated mice cancer patients respectively35 84 Although FMT reduces inflammation ulceration fewer effects corticosteroids anti TNF anti integrin agents extremely small sample size study lack mechanistic insight extensive validations84 Recent advances basic science Analysis faecal samples patients receiving radio therapy suggested patients radiation enteropathy showed lower bacterial diversity enrichment specific microbial taxa including Clostridium IV Roseburia85 FMT shown alleviate radiation induced GI toxicity increase survival rate irradiated mice improving GI tract function epithelial integrity Notably FMT thickens mucus layer irradiated mice upregulating expression Muc2 Glut1 Slc2a1 Pgk1 intestinal trefoil factor TFF3ITF1 multidrug resistance protein 1 MDR1 FMT amelio rates radiation induced bone marrow toxicity Compared FMT bone marrow transplant combination treat ment significantly increases survival rate irradiated mice86 suggesting FMT serve radioprotector improve prognosis patients cancer receiving radiotherapy In spite protective effect cancer therapy induced toxicities FMT associated risks Pathogens trans mitted recipients FMT As robust microbiolog ical screening essential abrogating risk transferring known pathogens especially ones carrying antimicrobial resistance Nonetheless remains challenging identify condi tions FMT true clinical potential Limited data knowledge role FMT cancer prevent predic tion patients response FMT Further analysis micro bial profile donors recipients associated mechanistic insights crucial effective FMT treatment patients87 BACTERIA DEPLETION BY ANTIBIOTICS OR OTHER MEANS Given contribution tumourigenesis carcinogenic bacteria depleted means prevent cancer delay tumour growth Among pathogens H pyloris role gastric tumourigenesis established88 89 Eradication H pylori combination amoxicillin clarithromycin patients early gastric cancer associ ated lower rates developing metachronous gastric cancer improvements grade glandular atrophy corpus90 Conversely analysis 125 441 cancer cases 490 510 control cases indicated antibiotic treatment positively correlated cancer risk91 92 Antibiotics associated reduced survival patients advanced renal cell carcinoma receiving anti programmed cell death ligand1 PD L1 monoclonal antibody mAb mono therapy93 suggesting removal commensals mines efficacy ICIs The conventional use antibiotics alters commensal microbiota leading collateral damage patients Novel tech nologies CRISPR Cas9 delivered phage94 95 targeting specific bacteria microbiomecancer interface needed minimise perturbation commensal micro biota ensure effective cancer treatment Notably admin istration irinotecan loaded dextran nanoparticles covalently linked azide modified phages target F nucleatum tumours augments effect chemotherapy CRC The phage treatment restricted GI tumours reducing poten tial toxicities associated therapy96 Ongoing clinical trials proven utility nanoparticles drug delivery increasing number nanomedicines approved indications97 Nanotechnologies target tumour associated bacteria release anticancer drugs controlled manner causing fewer effects patients98 99 Given implications nanotechnologies cancer prevention treatment efforts Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153 1871 Recent advances basic science directed evaluating toxicity effects stream mechanisms mediated nanoparticles BACTERIA COMPOSITIONAL MODULATION BY PROBIOTICS IN CANCER Numerous clinical trials conducted investigate effects probioticsprebiotics cancer Some trials100103 reported improved clinical outcome patients receiving probiotics others104 105 failed examine significant effect induced probiotics online supplementary S table 1 A prospective intervention study patients CRC revealed administration Lactobacillus acidophilus NCFM Bifidobacterium lactis Bl04 altered patients microbial profile The probiotics increased abundance butyrate producing bacteria Faecalibacterium Clostridiales spp decreasing abundance CRC associated genera including Fusobacterium Peptostreptococcus106 In addition altering microbial profile probiotics reported inhibit cancer progression animal models Using diethylnitrosamine DEN model rat hepatocarcinogenesis Zhang et al demon strated administration probiotic mixture VSL3 mitigated intestinal inflammation DEN treatment main tained intestinal mucosa integrity suppressed tumour growth107 A subsequent study demonstrated probiotic mixture Prohep reduced level Th17 cells tumour inhibiting hepatocellular carcinoma HCC progression subcutaneous transplant mouse model108 Clinical trials assessing therapeutic potential VSL3 patients cirrhosis109 non alcoholic fatty liver disease110 suggested probiotics improved severity diseases strongly linked development HCC111 Recently study Riehl et al delineated mechanism Lactobacillus rhamnosus GG LGG radioprotection Tumour bearing mice treated phosphate buffered saline irradiation LGG LGG followed irra diation The result demonstrated LGG releases lipoteichoic acid LTA binds TLR2 pericryptal macrophages promotes chemokine CXCL12 CXCL12 turn binds CXCR4 cyclo oxygenase2 expressing mesenchymal stem cells driving migration pericryptal region producing prostaglandin E2 protects epithelial stem cells radiation induced apoptosis112 Yet mechanism remains validated human In addition radioprotection probiotics manipulate host inflammatory status influencing efficacy cancer therapy113 Several clinical trials deny clinical benefits probiotics cancer treatment114 115 Treating patients head neck cancer cocktail Lactobacillus Bifidobacterium strains surgery improve clinical outcome patients Patients receiving probiotics receiving placebo similar rate postoperative infec tion displayed comparable level inflammatory markers diamine oxidase indicator gut permeability104 The conflicting results clinical trials explained interindi vidual variations microbiome host genome Colonisation function probiotics influenced indigenous micro biota gene expression profile host exogenous factors116118 Due variations remains challenging assess clinical benefits probiotics patients cancer In addition majority clinical trials probiotics shares limitations small sample size short duration treat ment lack follow examine long term effect probiotics patients Therefore designed studies critical evaluation probiotic treatment patients cancer Interestingly recent study investigated effects 11 strain probiotics autologous faecal microbiome transplan tation aFMT post antibiotic reconstitution mouse human microbiota The result indicated probiotics signifi cantly delayed microbiome reconstitution aFMT induced rapid near complete recovery days administra tion On basis finding aFMT instead probiotics reconstitute microbiome antibiotics perturbed patients116 ORGANOIDS PROVIDE DEEPER MECHANISTIC INSIGHTS INTO THE ROLE OF THE GUT MICROBIOTA IN CANCER Organoids cultured pluripotent stem cells tissues main tain characteristics respective tissues including histology expression markers119 With proper ties organoids adopted disease modelling drug screening120 Organoids overcome drawbacks current studies cell lines mouse models including limited access human samples intrinsic differences mouse models human physiology121 The addition bacteria organoid culture allows study hostbacteria interactions offers deeper mechanistic insight dimensional culture A study confirmed pro tumourigenic effect H pylori microinjection bacteria human gastric organoids The CagA protein H pylori binds c Met receptor organoid epithelial cells phosphorylates c Met promotes epithelial cell proliferation23 Moreover human monocyte derived dendritic cells DCs cocultured gastric organoids subsequently exposed H pylori The result showed DCs migrated interacted gastric epithe lial organoids migration enhanced H pylori infection122 This coculture recapitulated happened vivo bacterial infection DCs recruited gastric mucosa H pylori infection promote phagocytosis H pylori Furthermore fusion organoids coculture multiple organoids recently proposed enhance structural complexity functional maturation organ oids123 124 Clinically patient derived organoids predicting tumours sensitivity therapies FUTURE PERSPECTIVES AND CONCLUSIONS With advances sequencing technology development powerful computational tools research paradigm shifted association based approach mechanism based approach The mere presence absences certain bacterial species provides limited insight role gut microbiota cancers Indeed unravelling causal links bacteria cancers underlying mechanisms focus intense research Moreover altered viromes fungal microbiota implicated CRC125 126 suggesting microorganisms interact gut bacteria modulate patients response cancer treatment The integrated analysis gut microbiome interactions host anti cancer drugs exogenous factors127129 essential improving outcomes cancer patients online supplemen tary S table 2 Gnotobiotic animal models widely examine colonisation specific bacterial species gut biological functions context cancer provide proof principle needed direct interpret human studies24 130 However differences physiology intestinal tract dietary patterns genetics suggested mouse 1872 Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153 Recent advances basic science Figure 2 Preclinical mouse models sequencing data patients cancer valuable tools microbiome research contribute development novel therapeutics patients cancer Preclinical mouse models valuable tools dissect mechanisms defined bacteria absence microbes germ free mice presence limited number microbes antibiotic treatment However limitations selection bias prevent preclinical models fully recapitulating interactions gut microbiota cancer cells humans The antibiotic treatment select resistant bacteria promote fungal outgrowth confounding result experiment Other factors including housing environment diet genetic background mice influence microbial communities residing mice interaction tumour cells anticancer drugs To complement preclinical models cancer patients sequencing data examined terms host genome metabolome immune profile anticancer treatment Together mouse models meta analysis human sequencing data provide insights relationship gut microbiota cancer treatment Modulating gut microbiota selectively targeting cancer associated bacteria phages administering probiotics performing FMT reshape tumour microenvironment host immune responses augmenting efficacy anticancer drugs improving outcome cancer patients FMT faecal microbiota transplant microbiota differs significantly human microbiota131 132 Reproducibility mouse microbiota studies conclu sions interpreted caution findings validated extensively large scale multicentred clin ical trials Collaborative efforts elucidate role gut microbiota shaping responses cancer therapy evident ongoing trials evaluate effect FMT patients cancer impervious ICIs The teams conducting trials propose non responders lack beneficial bacteria critical antitumour effect immunotherapy transplanting bacteria responding patients non responders restore response ICIs NCT04130763 NCT04116775 NCT03353402 NCT03341143 These trials validations determine selective modu lation gut microbiota FMT probiotic treatment means enables patients cancer overcome resistance immune checkpoint therapy figure 2 Accumulating evidence underscored critical role gut microbiota cancer therapies Some bacterial species essential antitumour effect cancer treatment species attenuate efficacy cancer drugs diverse mechanisms Given relationships host gut microbiota cancer treatments research efforts directed investigate mechanisms bacteria modulate patients response treatment clinical outcomes In review explored dynamic interactions host gut microbiota cancer treat ments including chemotherapies immunotherapies Regard recent advances field microbiome research limitations current research hamper clinical applications bacterial therapies Of note strong associations distinct bacterial species cancers established underlying mechanisms remain elusive need extensive validation preclinical models clinical trials Nonetheless recent findings supported potential microbial markers enterotypes133 cancer diagnosis prognosis potential phage therapies targeted delivery cancer drugs potential FMT probiotics remodelling tumour microenvironment potentiating antitumour immunity The role microbiota cancer context dependent Bacteria Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153 1873 Recent advances basic science interact plethora host exogenous factors patients cancer influence tumourigenesis diverse mechanisms Overall comprehensive understanding functions distinct bacteria host physiology cancer treatment critical development personalised medicine enhances patients response cancer therapies modu lating gut microbial composition function Contributors WYC researched data article contributed substantially discussion content designed figures wrote article C YW reviewed edited manuscript JY designed content rewrite manuscript Funding The authors declared specific grant research funding agency public commercial profit sectors Competing interests None declared Patient consent publication Not required Provenance peer review Not commissioned externally peer reviewed Open access This open access article distributed accordance Creative Commons Attribution Non Commercial CC BY NC 40 license permits distribute remix adapt build work non commercially license derivative works different terms provided original work properly cited appropriate credit given changes indicated use non commercial See http creativecommons org licenses nc 4 0 ORCID iD Jun Yu http orcid org 0000 0001 5008 2153 REFERENCES 1 Riquelme E Zhang Y Zhang L et al Tumor microbiome diversity composition influence pancreatic cancer outcomes Cell 2019178795806 2 Pushalkar S Hundeyin M Daley D et al The pancreatic cancer microbiome promotes oncogenesis induction innate adaptive immune suppression Cancer Discov 2018840316 3 Virtue AT McCright SJ Wright JM et al The gut microbiota regulates white adipose tissue inflammation obesity family microRNAs Sci Transl Med 201911eaav1892 4 Foley KP Zlitni S Denou E et al Long term short term exposure obesity related microbiota promotes host insulin resistance Nat Commun 201894681 5 Sun L Ma L Ma Y et al Insights role gut microbiota obesity pathogenesis mechanisms therapeutic perspectives Protein Cell 20189397403 6 Koh A Molinaro A Ståhlman M et al Microbially produced imidazole propionate impairs insulin signaling mTORC1 Cell 201817594761 20 Thomas AM Manghi P Asnicar F et al Metagenomic analysis colorectal cancer datasets identifies cross cohort microbial diagnostic signatures link choline degradation Nat Med 20192566778 21 Wong SH Zhao L Zhang X et al Gavage fecal samples patients colorectal cancer promotes intestinal carcinogenesis germ free conventional mice Gastroenterology 2017153162133 22 Lv Y P Cheng P Zhang J Y et al Helicobacter pylori induced matrix metallopeptidase10 promotes gastric bacterial colonization gastritis Sci Adv 20195eaau6547 23 McCracken KW Catá EM Crawford CM et al Modelling human development disease pluripotent stem cell derived gastric organoids Nature 20145164004 24 Arthur JC Perez Chanona E Mühlbauer M et al Intestinal inflammation targets cancer inducing activity microbiota Science 20123381203 25 Wu S Rhee K J Albesiano E et al A human colonic commensal promotes colon tumorigenesis activation T helper type 17 T cell responses Nat Med 200915101622 26 Tsoi H Chu ESH Zhang X et al Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis colon cells induce proliferation causes dysplasia mice Gastroenterology 2017152141933 27 Long X Wong CC Tong L et al Peptostreptococcus anaerobius promotes colorectal carcinogenesis modulates tumour immunity Nat Microbiol 20194231930 28 Rubinstein MR Wang X Liu W et al Fusobacterium nucleatum promotes colorectal carcinogenesis modulating E cadherinβcatenin signaling FadA adhesin Cell Host Microbe 201314195206 29 Gholizadeh P Eslami H Kafil HS Carcinogenesis mechanisms Fusobacterium nucleatum Biomed Pharmacother 20178991825 30 Geller LT Barzily Rokni M Danino T et al Potential role intratumor bacteria mediating tumor resistance chemotherapeutic drug gemcitabine Science 2017357115660 31 Alexander JL Wilson ID Teare J et al Gut microbiota modulation chemotherapy efficacy toxicity Nat Rev Gastroenterol Hepatol 20171435665 32 Scott TA Quintaneiro LM Norvaisas P et al Host Microbe Co metabolism Dictates Cancer Drug Efficacy C elegans Cell 2017169e1844256 33 Tanoue T Morita S Plichta DR et al A defined commensal Consortium elicits CD8 T cells anti cancer immunity Nature 20195656005 34 Sivan A Corrales L Hubert N et al Commensal Bifidobacterium promotes antitumor immunity facilitates anti PD L1 efficacy Science 201535010849 35 Vétizou M Pitt JM Daillère R et al Anticancer immunotherapy CTLA4 blockade 36 relies gut microbiota Science 2015350107984 Iida N Dzutsev A Stewart CA et al Commensal bacteria control cancer response therapy modulating tumor microenvironment Science 201334296770 37 Viaud S Saccheri F Mignot G et al The intestinal microbiota modulates anticancer immune effects cyclophosphamide Science 20133429716 38 Viaud S Flament C Zoubir M et al Cyclophosphamide induces differentiation 7 Brown K Godovannyi A Ma C et al Prolonged antibiotic treatment induces Th17 cells cancer patients Cancer Res 2011716615 diabetogenic intestinal microbiome accelerates diabetes NOD mice Isme J 20161032132 8 Livanos AE Greiner TU Vangay P et al Antibiotic Mediated gut microbiome perturbation accelerates development type 1 diabetes mice Nat Microbiol 2016116140 9 Maini Rekdal V Bess EN Bisanz JE et al Discovery inhibition interspecies gut bacterial pathway levodopa metabolism Science 2019364eaau6323 10 Erny D Hrabě Angelis AL Jaitin D et al Host microbiota constantly control 39 Sethi V Kurtom S Tarique M et al Gut microbiota promotes tumor growth mice modulating immune response Gastroenterology 2018155337 40 Yu T Guo F Yu Y et al Fusobacterium nucleatum promotes chemoresistance colorectal cancer modulating autophagy Cell 2017170e1654863 41 Fukugaiti MH Ignacio A Fernandes MR et al High occurrence Fusobacterium nucleatum Clostridium difficile intestinal microbiota colorectal carcinoma patients Braz J Microbiol 201546113540 42 Castellarin M Warren RL Freeman JD et al Fusobacterium nucleatum infection prevalent human colorectal carcinoma Genome Res 201222299306 maturation function microglia CNS Nat Neurosci 20151896577 43 Kostic AD Gevers D Pedamallu CS et al Genomic analysis identifies association 11 Jin C Lagoudas GK Zhao C et al Commensal microbiota promote lung cancer development γδ T cells Cell 2019176e169981013 12 Tilg H Adolph TE Gerner RR et al The intestinal microbiota colorectal cancer Cancer Cell 20183395464 Fusobacterium colorectal carcinoma Genome Res 2012222928 44 Yamamura K Baba Y Nakagawa S et al Human microbiome Fusobacterium nucleatum esophageal cancer tissue associated prognosis Clin Cancer Res 201622557481 13 Zitvogel L Daillère R Roberti MP et al Anticancer effects microbiome 45 Hsieh Y Y Tung S Y Pan H Y et al Increased abundance Clostridium products Nat Rev Microbiol 20171546578 14 Garrett WS Cancer microbiota Science 2015348806 15 Polk DB Peek RM Helicobacter pylori gastric cancer Nat Rev Cancer 20101040314 16 Wong BC Y Lam SK Wong WM et al Helicobacter pylori eradication prevent gastric cancer high risk region China randomized controlled trial JAMA 200429118794 17 Dai Z Coker OO Nakatsu G et al Multi Cohort analysis colorectal cancer metagenome identified altered bacteria populations universal bacterial markers Microbiome 2018670 18 Wirbel J Pyl PT Kartal E et al Meta Analysis fecal metagenomes reveals global microbial signatures specific colorectal cancer Nat Med 20192567989 Fusobacterium gastric microbiota patients gastric cancer Taiwan Sci Rep 20188158 46 Shin JM Luo T Kamarajan P et al Microbial communities associated primary metastatic head neck squamous cell carcinoma high Fusobacterial low Streptococcal signature Sci Rep 201779934 47 Gaiser RA Halimi A Alkharaan H et al Enrichment oral microbiota early cystic precursors invasive pancreatic cancer Gut 201968218694 48 Gur C Ibrahim Y Isaacson B et al Binding Fap2 protein Fusobacterium nucleatum human inhibitory receptor TIGIT protects tumors immune cell attack Immunity 20154234455 49 Abed J Emgård JEM Zamir G et al Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment binding tumor expressed Gal GalNAc Cell Host Microbe 20162021525 19 Yachida S Mizutani S Shiroma H et al Metagenomic metabolomic analyses reveal distinct stage specific phenotypes gut microbiota colorectal cancer Nat Med 20192596876 50 Kaplan CW Ma X Paranjpe A et al Fusobacterium nucleatum outer membrane proteins Fap2 RadD induce cell death human lymphocytes Infect Immun 20107847748 1874 Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153 51 Uribe Herranz M Rafail S Beghi S et al Gut microbiota modulate dendritic cell 80 Hooper LV Wong MH Thelin A et al Molecular analysis commensal host Recent advances basic science antigen presentation radiotherapy induced antitumor immune response J Clin Invest 202013046679 52 Daillère R Vétizou M Waldschmitt N et al Enterococcus hirae Barnesiella intestinihominis facilitate cyclophosphamide induced therapeutic immunomodulatory effects Immunity 20164593143 53 Li Y Tinoco R Elmén L et al Gut microbiota dependent anti tumor immunity restricts melanoma growth Rnf5 mice Nat Commun 2019101492 54 Chaput N Lepage P Coutzac C et al Baseline gut microbiota predicts clinical response colitis metastatic melanoma patients treated ipilimumab Ann Oncol 201728136879 55 Ascierto PA Long GV Robert C et al Survival outcomes patients previously untreated BRAF wild type advanced melanoma treated nivolumab therapy year follow randomized phase 3 trial JAMA Oncol 2019518794 56 Vokes EE Ready N Felip E et al Nivolumab versus docetaxel previously treated advanced non small cell lung cancer CheckMate 017 CheckMate 057 3 year update outcomes patients liver metastases Ann Oncol 20182995965 57 Escudier B Motzer RJ Sharma P et al Treatment progression patients advanced renal cell carcinoma treated nivolumab CheckMate 025 Eur Urol 20177236876 58 Weber JS DAngelo SP Minor D et al Nivolumab versus chemotherapy patients advanced melanoma progressed anti CTLA4 treatment CheckMate 037 randomised controlled open label phase 3 trial Lancet Oncol 20151637584 59 Topalian SL Sznol M McDermott DF et al Survival durable tumor remission long term safety patients advanced melanoma receiving nivolumab J Clin Oncol 201432102030 60 Routy B Le Chatelier E Derosa L et al Gut microbiome influences efficacy PD1 based immunotherapy epithelial tumors Science 2018359917 61 Gopalakrishnan V Spencer CN Nezi L et al Gut microbiome modulates response anti PD1 immunotherapy melanoma patients Science 201835997103 62 Matson V Fessler J Bao R et al The commensal microbiome associated anti PD1 efficacy metastatic melanoma patients Science 20183591048 63 Frankel AE Coughlin LA Kim J et al Metagenomic shotgun sequencing unbiased metabolomic profiling identify specific human gut microbiota metabolites associated immune checkpoint therapy efficacy melanoma patients Neoplasia 20171984855 64 Quévrain E Maubert MA Michon C et al Identification anti inflammatory protein Faecalibacterium prausnitzii commensal bacterium deficient Crohns disease Gut 20166541525 65 Bachem A Makhlouf C Binger KJ et al Microbiota Derived Short Chain Fatty Acids Promote Memory Potential Antigen Activated CD8 T Cells Immunity 20195128597 66 Lu Y Chen J Zheng J et al Mucosal adherent bacterial dysbiosis patients colorectal adenomas Sci Rep 2016626337 67 Nakatsu G Li X Zhou H et al Gut mucosal microbiome stages colorectal carcinogenesis Nat Commun 201568727 68 Bullman S Pedamallu CS Sicinska E et al Analysis Fusobacterium persistence antibiotic response colorectal cancer Science 201735814438 69 Yan X Liu L Li H et al Clinical significance Fusobacterium nucleatum epithelial mesenchymal transition cancer stem cell markers stage IIIIV colorectal cancer patients Onco Targets Ther 201710503146 70 Wong SH Kwong TNY Chow T C et al Quantitation faecal Fusobacterium improves faecal immunochemical test detecting advanced colorectal neoplasia Gut 20176614418 71 Koi M Okita Y Carethers JM Fusobacterium nucleatum Infection Colorectal Cancer Linking Inflammation DNA Mismatch Repair Genetic Epigenetic Alterations J Anus Rectum Colon 201823746 72 Mima K Nishihara R Qian ZR et al Fusobacterium nucleatum colorectal carcinoma tissue patient prognosis Gut 201665197380 73 Tahara T Yamamoto E Suzuki H et al Fusobacterium colonic flora molecular features colorectal carcinoma Cancer Res 20147413118 74 Hamada T Zhang X Mima K et al Fusobacterium nucleatum Colorectal Cancer Relates Immune Response Differentially Tumor Microsatellite Instability Status Cancer Immunol Res 20186132736 75 Ma C Han M Heinrich B et al Gut microbiome mediated bile acid metabolism regulates liver cancer NKT cells Science 2018360pii eaan5931 76 Bachmann R Leonard D Delzenne N et al Novel insight role microbiota colorectal surgery Gut 20176673849 77 Guyton K Alverdy JC The gut microbiota gastrointestinal surgery Nat Rev Gastroenterol Hepatol 2017144354 78 Everard A Belzer C Geurts L et al Cross Talk Akkermansia muciniphila intestinal epithelium controls diet induced obesity Proc Natl Acad Sci U S A 2013110906671 79 Jones RM Luo L Ardita CS et al Symbiotic lactobacilli stimulate gut epithelial proliferation Nox mediated generation reactive oxygen species Embo J 201332301728 microbial relationships intestine Science 20012918814 81 Hyoju SK Klabbers RE Aaron M et al Oral polyphosphate suppresses bacterial collagenase production prevents anastomotic leak Serratia marcescens Pseudomonas aeruginosa Ann Surg 201826711128 82 van Praagh JB Goffau MC Bakker IS et al Mucus microbiome anastomotic tissue surgery predictive value colorectal anastomotic leakage Ann Surg 20192699116 83 Dubin K Callahan MK Ren B et al Intestinal microbiome analyses identify melanoma patients risk checkpoint blockade induced colitis Nat Commun 2016710391 84 Wang Y Wiesnoski DH Helmink BA et al Fecal microbiota transplantation refractory immune checkpoint inhibitor associated colitis Nat Med 20182418048 85 Reis Ferreira M Andreyev HJN Mohammed K et al Microbiota radiotherapy induced gastrointestinal effects MARs study large pilot study microbiome acute late radiation enteropathy Clin Cancer Res 2019256487500 86 Cui M Xiao H Li Y et al Faecal microbiota transplantation protects radiation induced toxicity EMBO Mol Med 2017944861 87 Giles EM DAdamo GL Forster SC The future faecal transplants Nat Rev Microbiol 201917719 88 Romano M Ricci V Zarrilli R Mechanisms disease Helicobacter pylori related gastric carcinogenesisimplications chemoprevention Nat Clin Pract Gastroenterol Hepatol 2006362232 89 Peek RM Blaser MJ Helicobacter pylori gastrointestinal tract adenocarcinomas Nat Rev Cancer 200222837 90 Choi IJ Kook M C Kim Y I et al Helicobacter pylori therapy prevention metachronous gastric cancer N Engl J Med 2018378108595 91 Boursi B Mamtani R Haynes K et al Recurrent antibiotic exposure promote cancer formationAnother step understanding role human microbiota Eur J Cancer 201551265564 92 Cao Y Wu K Mehta R et al Long Term use antibiotics risk colorectal adenoma Gut 2018676728 93 Derosa L Hellmann MD Spaziano M et al Negative association antibiotics clinical activity immune checkpoint inhibitors patients advanced renal cell non small cell lung cancer Ann Oncol 201829143744 94 Bikard D Euler CW Jiang W et al Exploiting CRISPR Cas nucleases produce sequence specific antimicrobials Nat Biotechnol 201432114650 95 Citorik RJ Mimee M Lu TK Sequence Specific antimicrobials efficiently delivered RNA guided nucleases Nat Biotechnol 20143211415 96 Zheng D W Dong X Pan P et al Phage guided modulation gut microbiota mouse models colorectal cancer augments responses chemotherapy Nat Biomed Eng 2019371728 97 Anselmo AC Mitragotri S Nanoparticles clinic update Bioeng Transl Med 20194e10143 98 Song W Anselmo AC Huang L Nanotechnology intervention microbiome cancer therapy Nat Nanotechnol 2019141093103 99 Angsantikul P Thamphiwatana S Zhang Q et al Coating nanoparticles gastric epithelial cell membrane targeted antibiotic delivery Helicobacter pylori infection Adv Ther 20181pii 1800016 100 Flesch AT Tonial ST Contu PDEC et al Perioperative synbiotics administration decreases postoperative infections patients colorectal cancer randomized double blind clinical trial Rev Col Bras Cir 20174456773 101 Theodoropoulos GE Memos NA Peitsidou K et al Synbiotics gastrointestinal function related quality life elective colorectal cancer resection Ann Gastroenterol 2016295662 102 Mego M Chovanec J Vochyanova Andrezalova I et al Prevention irinotecan induced diarrhea probiotics randomized double blind placebo controlled pilot study Complement Ther Med 20152335662 103 Tian Y Li M Song W et al Effects probiotics chemotherapy patients lung cancer Oncol Lett 201917283648 104 Lages PC Generoso SV Correia MITD Postoperative symbiotic patients head neck cancer double blind randomised trial Br J Nutr 20181191905 105 Consoli MLD da Silva RS Nicoli JR et al Randomized clinical trial impact oral administration Saccharomyces boulardii gene expression intestinal cytokines patients undergoing colon resection JPEN J Parenter Enteral Nutr 201640111421 106 Hibberd AA Lyra A Ouwehand AC et al Intestinal microbiota altered patients colon cancer modified probiotic intervention BMJ Open Gastroenterol 20174e000145 107 Zhang H L Yu L X Yang W et al Profound impact gut homeostasis chemically induced pro tumorigenic inflammation hepatocarcinogenesis rats J Hepatol 20125780312 108 Li J Sung CYJ Lee N et al Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth mice Proc Natl Acad Sci U S A 2016113E130615 Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153 1875 Recent advances basic science 109 Dhiman RK Rana B Agrawal S et al Probiotic VSL3 reduces liver disease severity hospitalization patients cirrhosis randomized controlled trial Gastroenterology 2014147132737 110 Alisi A Bedogni G Baviera G et al Randomised clinical trial The beneficial effects VSL3 obese children non alcoholic steatohepatitis Aliment Pharmacol Ther 201439127685 111 Michelotti GA Machado MV Diehl AM Nafld NASH liver cancer Nat Rev Gastroenterol Hepatol 20131065665 112 Riehl TE Alvarado D Ee X et al Lactobacillus rhamnosus GG protects intestinal epithelium radiation injury release lipoteichoic acid macrophage activation migration mesenchymal stem cells Gut 201968100313 113 Zaharuddin L Mokhtar NM Muhammad Nawawi KN et al A randomized double blind placebo controlled trial probiotics post surgical colorectal cancer BMC Gastroenterol 201919131 114 Anderson ADG McNaught CE Jain PK et al Randomised clinical trial synbiotic therapy elective surgical patients Gut 2004532415 115 McNaught CE Woodcock NP MacFie J et al A prospective randomised study probiotic Lactobacillus plantarum 299v indices gut barrier function elective surgical patients Gut 20025182731 116 Suez J Zmora N Zilberman Schapira G et al Post Antibiotic gut mucosal microbiome reconstitution impaired probiotics improved autologous FMT Cell 2018174140623 117 Zmora N Zilberman Schapira G Suez J et al Personalized gut mucosal colonization resistance empiric probiotics associated unique host microbiome features Cell 2018174e211388405 118 Morgan XC Segata N Huttenhower C Biodiversity functional genomics human microbiome Trends Genet 201329518 120 Broutier L Mastrogiovanni G Verstegen MM et al Human primary liver cancer derived organoid cultures disease modeling drug screening Nat Med 201723142435 121 Prior N Inacio P Huch M Liver organoids basic research therapeutic applications Gut 201968222837 122 Sebrell TA Hashimi M Sidar B et al A novel gastric spheroid culture model reveals chemokine dependent recruitment human dendritic cells gastric epithelium Cell Mol Gastroenterol Hepatol 2019815771 123 Jin Y Kim J Lee JS et al Vascularized liver organoids generated induced hepatic tissue dynamic liver specific microenvironment drug testing platform Adv Funct Mater 2018281801954 124 Koike H Iwasawa K Ouchi R et al Modelling human hepato biliary pancreatic organogenesis foregut midgut boundary Nature 20195741126 125 Coker OO Nakatsu G Dai RZ et al Enteric fungal microbiota dysbiosis ecological alterations colorectal cancer Gut 20196865462 126 Nakatsu G Zhou H Wu WKK et al Alterations enteric virome associated colorectal cancer survival outcomes Gastroenterology 201815552941 127 Zhernakova A Kurilshikov A Bonder MJ et al Population Based metagenomics analysis reveals markers gut microbiome composition diversity Science 20163525659 128 Blaser MJ Antibiotic use consequences normal microbiome Science 20163525445 129 David LA Maurice CF Carmody RN et al Diet rapidly reproducibly alters human gut microbiome Nature 201450555963 130 Lepage P Leclerc MC Joossens M et al A metagenomic insight guts microbiome Gut 20136214658 131 Hugenholtz F Vos WM Mouse models human intestinal microbiota research critical evaluation Cell Mol Life Sci 20187514960 132 Xiao L Feng Q Liang S et al A catalog mouse gut metagenome Nat 119 Bartfeld S Bayram T van Wetering M et al In vitro expansion human gastric Biotechnol 20153311038 epithelial stem cells responses bacterial infection Gastroenterology 201514812636 133 Arumugam M Raes J Pelletier E et al Enterotypes human gut microbiome Nature 201147317480 1876 Cheng WY et al Gut 20206918671876 doi101136gutjnl2020321153